

---

## AcouSort selected by EIC for participation in leading medical exhibition for the third time

AcouSort has been selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2023 in Boston, USA, after a highly competitive evaluation process. AcouSort is thereby one of 17 European companies selected by the EU for full sponsorship at America's leading medical exhibition, taking place in Boston June 5-8.

During the convention, AcouSort will mainly focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and cell therapy applications. As BIO 2023 attracts 14,000+ biotechnology and pharma leaders, it offers a fantastic opportunity to discover new possibilities and promising partnerships.

The 2023 BIO International Convention will feature more than 100 interactive sessions across four days covering business development, a variety of therapeutic areas as well as next generation biotherapeutics. The delegation of the European Pavilion was selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business out of their participation.

*"It is of course incredibly inspiring to be one of the 17 European SMEs or startups selected by EIC for participation at BIO 2023. This is one of the most important conferences in the healthcare and biotech industry, where most leading companies are represented. AcouSort has previously been selected by EIC for participation at BIO 2022 and Medica 2022. It is exceptionally rewarding to be selected by the EIC for a third time and we regard this as a true seal of excellence of our company,"* says AcouSort's CEO Torsten Freltoft.

### For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

---

### About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.